Abstract
The growth of human breast tumor cells is regulated through signaling involving cell surface growth factor receptors and nuclear receptors of the steroid/thyroid/retinoid receptor gene family. Retinoic acid receptors (RARs), members of the steroid/thyroid hormone receptor gene family, are ligand-dependent transcription factors, which have in vitro and in vivo growth inhibitory activity against breast cancer cells. RAR-agonists inhibit the proliferation of many human breast cancer cell lines, particularly those whose growth is stimulated by estradiol (E2) or growth factors. Additionally, RAR-agonists and synthetic retinoids such as Ferentinide have been shown to induce apoptosis in malignant breast cells but not normal breast cells. To better define the genes involved in RAR-mediated growth inhibition of breast cancer cells, we used oligonucleotide microarray analysis to create a database of genes that are potentially regulated by RAR-agonists in breast cancer cells. We found that PDCD4 (programmed cell death 4), a tumor suppressor gene presently being evaluated as a target for chemoprevention, was induced about three-fold by the RARα-selective agonist Am580, in T-47D breast cancer cells. RAR pan-agonists and Am580, but not retinoid X receptors (RXR)-agonists, stimulate the expression of PDCD4 in a wide variety of retinoid-inhibited breast cancer cell lines. RAR-agonists did not induce PDCD4 expression in breast cancer cell lines, which were not growth inhibited by retinoids. We also observed that antiestrogen and the HER-2/neu antagonist, Herceptin (Trastuzumab), also induced PDCD4 expression in T-47D cells, suggesting that PDCD4 may play a central role in growth inhibition in breast cancer cells. Transient overexpression of PDCD4 in T-47D (ER+, RAR+) and MDA-MB-231 (ER−, RAR−) cells resulted in apoptotic death, suggesting a role for PDCD4 in mediating apoptosis in breast cancer cells. PDCD4 protein expression has previously been reported in small ductal epithelium of normal breast. To date, there has been no report of induction of PDCD4 expression by RAR-agonists, antiestrogen or HER2/neu antagonist in breast cancer cells and its potential role in apoptosis in these cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Accession codes
References
Afonja O, Raaka BM, Huang A, Das S, Zhao X, Helmer E, Juste D and Samuels HH . (2002). Oncogene, 21, 7850–7860.
Allenby G, Bocquel MT, Saunders M, Kazmer S, Speck J, Rosenberger M, Lovey A, Kastner P, Grippo JF, Chambon P and Levin AA . (1993). Proc. Natl. Acad. Sci. USA, 90, 30–34.
Amos B and Lotan R . (1990). Methods Enzymol., 190, 217–225.
Azzoni L, Zatsepina O, Abebe B, Bennett IM, Kanakaraj P and Perussia B . (1998). J. Immunol., 161, 3493–3500.
Bange J, Zwick E and Ullrich A . (2001). Nat. Med., 7, 548–552.
Bohm M, Sawicka K, Siebrasse JP, Brehmer-Fastnacht A, Peters R and Klempnauer KH . (2003). Oncogene, 22, 4905–4910.
Chen Y, Knosel T, Kristiansen G, Pietas A, Garber ME, Matsuhashi S, Ozaki I and Petersen I . (2003). J. Pathol., 200, 640–646.
Chomczynski P and Sacchi N . (1987). Anal. Biochem., 162, 156–159.
Christine Pratt MA, Niu M and White D . (2003). J. Cell Biochem., 90, 692–708.
Cmarik JL, Min H, Hegamyer G, Zhan S, Kulesz-Martin M, Yoshinaga H, Matsuhashi S and Colburn NH . (1999). Proc. Natl. Acad. Sci. USA, 96, 14037–14042.
Dietze EC, Caldwell LE, Marcom K, Collins SJ, Yee L, Swisshelm K, Hobbs KB, Bean GR and Seewaldt VL . (2002). Microsc. Res. Tech., 59, 23–40.
Fanjul A, Dawson MI, Hobbs PD, Jong L, Cameron JF, Harlev E, Graupner G, Lu XP and Pfahl M . (1994). Nature, 372, 107–111.
Fitzgerald P, Teng M, Chandraratna RA, Heyman RA and Allegretto EA . (1997). Cancer Res., 57, 2642–2650.
Gianni M, Li Calzi M, Terao M, Guiso G, Caccia S, Barbui T, Rambaldi A and Garattini E . (1996). Blood, 87, 1520–1531.
Greenlee RT, Murray T, Bolden S and Wingo PA . (2000). CA Cancer J. Clin., 50, 7–33.
Grunt TW . (2003). Cancer Lett., 189, 147–156.
Gumireddy K, Sutton LN, Phillips PC and Reddy CD . (2003). Clin. Cancer Res., 9, 4052–4059.
Han QX, Allegretto EA, Shao ZM, Kute TE, Ordonez J, Aisner SC, Rishi AK and Fontana JA . (1997). Daign. Mol. Pathol., 6, 42–48.
Jansen AP, Camalier CE, Stark C and Colburn NH . (2004). Mol. Cancer Ther., 3, 103–110.
Jansen AP, Dean M and Colburn NH . (2003). Proc. Amer. Assoc. Cancer Res., 44, 938 (Abstract #4723).
Jurisicova A, Latham KE, Casper RF and Varmuza SL . (1998). Mol. Reprod. Dev., 51, 243–253.
Kagechika H, Kawachi E, Hashimoto Y, Himi T and Shudo K . (1988). J. Med. Chem., 31, 2182–2192.
Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM and Bast Jr RC . (2003). J. Biol. Chem., 278, 23441–23450.
Lombet A, Zujovic V, Kandouz M, Billardon C, Carvajal-Gonzalez S, Gompel A and Rostene W . (2001). Eur. J. Biochem., 268, 1352–1362.
Mangelsdorf DJ . (1994). Nutr. Rev., 52, S32–S44.
Mangelsdorf DJ, Borgmeyer U, Heyman RA, Zhou JY, Ong ES, Oro AE, Kakizuka A and Evans RM . (1992). Genes Dev., 6, 329–344.
Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P and Evans RM . (1995). Cell, 83, 835–839.
Mangiarotti R, Danova M, Alberici R and Pellicciari C . (1998). Br. J. Cancer, 77, 186–191.
Matsuhashi S, Watanabe T and Hori K . (1987). Exp. Cell Res., 170, 351–362.
Matsuhashi S, Yoshinaga H, Yatsuki H, Tsugita A and Hori K . (1997). Res. Commun. Biochem. Cell. Mol. Biol., 1, 109–120.
McPherson K, Steel CM and Dixon JM . (2000). BMJ, 321, 624–628.
Niu MY, Menard M, Reed JC, Krajewski S and Pratt MA . (2001). Oncogene, 20, 3506–3518.
Offterdinger M, Schneider SM and Grunt TW . (2003). J. Cell Physiol., 195, 260–275.
Onishi Y, Hashimoto S and Kizaki H . (1998). Gene, 215, 453–459.
Orlandi M, Mantovani B, Ammar K, Avitabile E, Dal Monte P and Bartolini G . (2003). Med. Princ. Pract., 12, 164–169.
Raffo P, Emionite L, Colucci L, Belmondo F, Moro MG, Bollag W and Toma S . (2000). Anticancer Res., 20, 1535–1543.
Roman SD, Ormandy CJ, Manning DL, Blamey RW, Nicholson RI, Sutherland RL and Clarke CL . (1993). Cancer Res., 53, 5940–5945.
Salbert G, Fanjul A, Piedrafita FJ, Lu XP, Kim SJ, Tran P and Pfahl M . (1993). Mol. Endocrinol., 7, 1347–1356.
Seewaldt VL, Caldwell LE, Johnson BS, Swisshelm K, Collins SJ and Tsai S . (1997). Exp. Cell Res., 236, 16–28.
Seewaldt VL, Dietze EC, Johnson BS, Collins SJ and Parker MB . (1999). Cell Growth Differ., 10, 49–59.
Seewaldt VL, Johnson BS, Parker MB, Collins SJ and Swisshelm K . (1995). Cell Growth Differ., 6, 1077–1088.
Sheikh MS, Shao ZM, Li XS, Dawson M, Jetten AM, Wu S, Conley BA, Garcia M, Rochefort H and Fontana JA . (1994). J. Biol. Chem., 269, 21440–21447.
Shibahara K, Asano M, Ishida Y, Aoki T, Koike T and Honjo T . (1995). Gene, 166, 297–301.
Soejima H, Miyoshi O, Yoshinaga H, Masaki Z, Ozaki I, Kajiwara S, Niikawa N, Matsuhashi S and Mukai T . (1999). Cytogenet. Cell Genet., 87, 113–114.
Sun SY and Lotan R . (2002). Crit. Rev. Oncol. Hematol., 41, 41–55.
Suzuki T, Moriya T, Sugawara A, Ariga N, Takabayashi H and Sasano H . (2001). Breast Cancer Res. Treat., 65, 31–40.
Tari AM, Lim SJ, Hung MC, Esteva FJ and Lopez-Berestein G . (2002). Oncogene, 21, 5224–5232.
Toma S, Isnardi L, Raffo P, Dastoli G, De Francisci E, Riccardi L, Palumbo R and Bollag W . (1997). Int. J. Cancer, 70, 619–627.
Veselska R, Zitterbart K, Jelinkova S, Neradil J and Svoboda A . (2003). Oncol. Rep., 10, 1049–1058.
Wilcken NR, Musgrove EA and Sutherland RL . (1997a). Int. J. Cancer, 70, 291–296.
Wilcken NR, Prall OW, Musgrove EA and Sutherland RL . (1997b). Clin. Cancer Res., 3, 849–854.
Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S, Lockett SJ, Sonenberg N and Colburn NH . (2003a). Mol. Cell. Biol., 23, 26–37.
Yang HS, Jansen AP, Nair R, Shibahara K, Verma AK, Cmarik JL and Colburn NH . (2001). Oncogene, 20, 669–676.
Yang HS, Knies JL, Stark C and Colburn NH . (2003b). Oncogene, 22, 3712–3720.
Ye X, Wu Q, Liu S, Lin X, Zhang B, Wu J, Cai J, Zhang M and Su W . (2004). Int. J. Biochem. Cell Biol., 36, 98–113.
Yoshinaga H, Matsuhashi S, Ahanek J, Masaki Z and Hori K . (1997). Res. Commun. Biochem. Cell. Mol. Biol., 1, 121–131.
Yoshinaga H, Matsuhashi S, Fujiyama C and Masaki Z . (1999). Pathol. Int., 49, 1067–1077.
Zhang Z and DuBois RN . (2001). Oncogene, 20, 4450–4456.
Acknowledgements
We are grateful to Dr F Muggia for providing us with Herceptin used in this study. This research was supported by the Robert Wood Johnson Foundation Grant (038398) (OA), NIH Grant K12CA01713 (OA), NIH grant DK16636 (HHS), and a grant form the Entertainment Industry Foundation (EIF) (HHS).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Afonja, O., Juste, D., Das, S. et al. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis. Oncogene 23, 8135–8145 (2004). https://doi.org/10.1038/sj.onc.1207983
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1207983
Keywords
This article is cited by
-
The molecular basis of translation initiation and its regulation in eukaryotes
Nature Reviews Molecular Cell Biology (2024)
-
PDCD4 controls the G1/S-phase transition in a telomerase-immortalized epithelial cell line and affects the expression level and translation of multiple mRNAs
Scientific Reports (2020)
-
Cytoplasmic localization of programmed cell death 4 contributes to its anti-apoptotic function
Molecular and Cellular Biochemistry (2018)
-
miR-374a-CCND1-pPI3K/AKT-c-JUN feedback loop modulated by PDCD4 suppresses cell growth, metastasis, and sensitizes nasopharyngeal carcinoma to cisplatin
Oncogene (2017)
-
A novel mechanism for the control of translation of specific mRNAs by tumor suppressor protein Pdcd4: inhibition of translation elongation
Oncogene (2015)